INTRODUCTION

The two major concerns of a drug are safety and efficacy. The efficacy of a drug can be quantified with relative ease; the same cannot be said about safety. This is because the adverse effect of a drug may be uncommon (very serious) and many patients may be affected or subjected to a potential risk before the relationship with the drug is established [1,2]. The World Health Organization (WHO) has defined adverse drug reaction (ADR) as “a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function” [3]. One of the important causes of morbidity and mortality worldwide is ADRs. Estimates suggest that ADRs are the fourth major cause of death in the United States recently [4]. The major key role in Pharmacovigilance programs is played by healthcare professionals such as physicians, pharmacist, and nurses [5,6], but with an estimated median underreporting rate (defined as the percentage of ADRs detected from intensive data collection that was not reported to relevant spontaneous reporting systems) of 94%, it is noted that underreporting is very common [7], and occurs frequently for serious and unlabeled reactions [8,9]. The detection of important ADRs is delayed due to this. According to the studies from various settings, the inadequate knowledge and attitude of healthcare professionals about Pharmacovigilance are associated with a high degree of underreporting [10-15]. It is estimated that only 6–10% of all ADRs are reported [16,17].

The word “Pharmacovigilance” is as follows: Pharmakon (Greek word for “drug”) and vigilare (Latin word for “to keep watch”) [18]. It is a growing discipline because of the rise of ADRs[19,20] that ensure patient care and safety using the medicines in the best way for the treatment or prevention of ADRs [21]. Pharmacovigilance is defined by the WHO as “the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other possible drug-related problem, particularly long-term and short-term adverse effects of medicines” [22]. Due to the difference in drug response among individuals, various prescribing habits, drug regulatory system, and availability of drugs, it has been recommended for every country to set up their own Pharmacovigilance programs [23]. The common problem faced in Pharmacovigilance program is underreporting of ADRs [24,25]. Inadequate funds, lack of trained staff, and lack of awareness about detection, communication, and spontaneous monitoring of ADRs may be the reason, gross underreporting of ADRs is a cause of concern [7,8]. The success and effectiveness of any Pharmacovigilance system highly depend on the participation of all health care professionals, and thus, physicians, pharmacists, and nurses are also important healthcare professionals responsible for Pharmacovigilance activities and ADR reporting during their practice.

In India, Pharmacovigilance is still in early stage and there exists very limited knowledge about this discipline. Like most of the Pharmacovigilance programs around the world, even the Pharmacovigilance Program of India (PvPI) suffers from underreporting of ADRs by the healthcare professionals which leads in detecting important ADRs [26]. ADR monitoring centers (AMCs) in India are being set up across the country under PvPI reinitiated in 2010. This whole program is under the Central Drugs Standard Control
Organization, Ministry of Health and Family Welfare, Government of India [27]. As per PvPI, it is mandatory for every teaching hospital to have a Pharmacovigilance center/cell. Therefore, this study was conducted among healthcare professionals to assess their awareness on Pharmacovigilance and to evaluate the impact of an educational intervention for creating awareness on Pharmacovigilance among nursing staff and student’s in Bengaluru, Karnataka, India.

METHODS

Study design and site
A questionnaire survey was conducted in two tertiary care hospitals in Bengaluru, Karnataka, India.

Source of data
The required information for the study was obtained from nursing professionals and students of study site.

Sample size
This study involved 127 participants, of which only 103 (37 nursing staff and 66 nursing students) returned the filled pre- and post-questionnaire.

Design of questionnaire
Questionnaire containing 20 questions was given to all the participants. The questionnaire was designed in such a way to assess the demographic details of the participants and had three sections containing 11 knowledge-based, 5 attitudes-based, and 4 practice-related questions, respectively.

Collection of data
The pre-knowledge, attitude, and perception (KAP) questionnaire was initially administered to all 127 participants, and the purpose of the study was explained. A theoretical presentation on what is Pharmacovigilance, PvPI, ADRs (i.e., in terms of definition, causality assessment, and seriousness), role of nursing staff in reporting importance of reporting the ADRs, and its effect on patient safety and various tools to report ADR (i.e., forms and mobile app) was used in the educational intervention. Following the educational intervention program on Pharmacovigilance conducted by the Pharmacovigilance associates of ADR monitoring center, all participants in the study were given post-KAP questionnaire and their responses were documented. A total of 5 intervention programs were conducted to cover the study population.

Data analysis and statistics
The scores of pre- and post-test questionnaires were analyzed to study the effectiveness of educational intervention among the participants. The pre-KAP questionnaire was analyzed question wise, and their percentage value was calculated. The Statistical Package for Social Sciences statistical software, version 16, was used to analyze the data.

Validation of questionnaire
The questionnaire was a 20 item inventory titled “The standard KAP questionnaire” which was validated at one of the site. It contained 20 items that were adapted from the previous studies and literature.

RESULTS

The present study involved 103 (81.1%) participants from 127, who participated and responded.

Categorization on the demographic details of the participants involved in the study was done based on gender distribution, professional status, and experience. The thoroughly analyzed results are reported in Tables 1 and 2.

The KAP of the participants toward Pharmacovigilance and ADR reporting was evaluated by comparing the pre- and post-KAP percentage of responses. Table 3 contains a comparison of the values and percentage of positive and negative responses for the pre- and post-KAP questionnaire, respectively.

The results of Q No 6, 19 & 20 are given in graphical representation as the participants were allowed to choose multiple answers.

Fig. 1 gives a detailed overview of the responses for the knowledge-based question No 6. Participants were allowed to choose more than one option. The respondents’ knowledge toward reporting of ADRs based on the seriousness indicates that they preferred to report serious and life-threatening cases 41.74% in the pre-questionnaire, which eventually changed in the post-questionnaire outcome, suggest that all ADRs must be reported irrespective of seriousness 87.37%.

The participants reason cited for not reporting ADRs and practice-based Q-19 are listed in Fig. 2. Lack of knowledge (48.54%) and whom to report (28.15%) the ADR, difficulty to pinpoint suspected drug (34.95%), and busy schedule (32.03%) were the main reasons cited before the educational intervention.

Methods preferred for ADR reporting practice-based Q 20 are depicted in Fig. 3. Opinion on their preferred mode of reporting was sought from the respondents. Most preferred was direct contact 60.19% pre-KAP. Post-KAP results show interest in reporting through Android application 32.03% and Email 27.18%.

DISCUSSION

It is not possible to prevent every ADR, but the knowledge of nursing staff in this field is very effective to decrease the rate of occurrence of ADRs [28]. It is important for the nursing staff to participate in spontaneous reporting scheme because they spend more time in the wards and it is most likely that any acute ADR will first be observed by them. In countries where nurses are already participating in the ADR reporting scheme, studies have shown that they indeed contribute positively toward the promotion of ADR reporting [29,30]. Shalini and Mohan [31] and Arjun et al. [32] studies have suggested that the percentage of awareness among the dental and nursing staff was surprisingly negligible and increasing awareness in nursing students and nursing staff can increase the number of ADR reports. In our study, one focus of educational intervention was to increase awareness in nursing professionals on Pharmacovigilance and PvPI, as they can play an important role in making the Pharmacovigilance program more efficacious since their work nature involves close contact with the patients for a longer duration [33]. The increase in the positive response in pre- and post-KAP questions (1–20) of the standard KAP questionnaire was clearly evident. The participants’ response on question 01 and 02 were 49.51%–80.58% after the intervention and 16.50%–74.75% after the intervention, respectively.

Fig. 1 shows a positive response to educational intervention suggesting that 87.73% post-KAP response on reporting all ADRs. The percentage of overall respondents who realized the importance of ADR reporting increased from 70% to 97% from pre intervention to post intervention.

| Designation | Gender distribution | Total number of participants n=103 (%) |
|-------------|---------------------|--------------------------------------|
|             | Male (%)            | Female (%)                           |
| B.Sc. nursing students | 4 (6.06) | 62 (93.94) | 66 (64.07) |
| Nursing staff | 8 (21.62) | 29 (78.38) | 37 (35.93) |
| Total | 12 (11.66) | 91 (88.34) | 103 |

Table 2: Experience of the participants

| Age group | Participants |
|-----------|--------------|
| <10 years | 82           |
| More than 10 years | 21           |
This shows that the educational intervention was well received by the participants. Question No -8 shows that 56% of staff and 24% of students answered yes in pre-KAP to 91% of staff and 89% of student post-KAP. Kamtane and Jayawardhani also shows that a significant number of the respondents were not aware of the existence of a national Pharmacovigilance center in India [34]. The lack of awareness of participants about the existence of the PvPI and ADR reporting system (Table 3) is reflected in the result, which would ultimately affect the reporting. Therefore, personal communication and advertisement appear necessary to enhance reporting and create awareness about Pharmacovigilance program and AMC’s. Question 9 shows statistically significance at p<0.001; The knowledge about the existence of nearby AMC found increased from 26.21% at prior to intervention to 73.78% post intervention. As per Gupta et al [35] study, many healthcare professionals (75.51%) accepted that reporting ADR and teaching healthcare professionals on Pharmacovigilance are necessary.
positive response rate of 76.69% before to 98.10% and 73.78% before to 96.11% after the educational intervention program, respectively, for question 12 and 13 indicates that participants felt that ADR reporting is necessary and thinks that it will increase patient safety. However, question 14 shows that legal fear for reporting needs to be changed. Nursing staff should accept ADR reporting as a professional obligation and overcome the fear. To remove misconceptions and modify, the attitude of nurses toward reporting personal discussions and awareness programs will be more helpful.

Question 15 shows that 95.14% of participants felt ADR monitoring center should be present in every hospital after the educational

| Q No | KAP                                                                 | Pre-KAP responses (%) | Post-KAP responses (%) | p value |
|------|----------------------------------------------------------------------|-----------------------|------------------------|---------|
| 1    | Are you familiar with the term Pharmacovigilance?                    |                       |                        | <0.0001 |
|      | Yes                                                                  | 51 (49.51)            | 83 (80.58)             |         |
|      | No                                                                   | 52 (50.49)            | 20 (19.41)             |         |
| 2    | Pharmacovigilance is the study that relates to:                      |                       |                        | <0.0001 |
|      | Safe, effective, appropriate, and economic use of medicines           | 6 (5.82)              | 3 (2.91)               |         |
|      | Therapeutic drug monitoring                                          | 3 (2.91)              | 0                      |         |
|      | Detection, assessment, understanding, and prevention of adverse      | 17 (16.50)            | 77 (74.75)             |         |
|      | effectsW                                                             | All the above         |                        |         |
|      |                                                                       | 77 (74.75)            | 23 (22.33)             | 0.0449  |
| 3    | Do you believe all the drugs available in the market are safe?       |                       |                        |         |
|      | Yes                                                                  | 8 (7.76)              | 13 (12.62)             |         |
|      | No                                                                   | 95 (92.24)            | 90 (87.38)             |         |
| 4    | Do you think ADR reporting is important?                             |                       |                        |         |
|      | Yes                                                                  | 72 (69.90)            | 100 (97.05)            | 0.0282  |
|      | No                                                                   | 31 (30.10)            | 3 (2.92)               |         |
| 5    | Should ADRs be reported only by physicians?                          |                       |                        |         |
|      | Yes                                                                  | 84 (81.55)            | 60 (58.25)             | 0.0282  |
|      | No                                                                   | 19 (18.45)            | 43 (41.74)             |         |
| 7    | Are you aware of any drug that has been banned due to ADR?           |                       |                        | <0.0001 |
|      | Yes                                                                  | 22 (21.35)            | 89 (86.40)             |         |
|      | No                                                                   | 81 (78.64)            | 14 (13.60)             |         |
| 8    | Are you aware of Pharmacovigilance Program of Indian Pharmacopeia    |                       |                        | <0.0001 |
|      | commission, Ministry of Health, Government of India?                  |                       |                        |         |
|      | Yes                                                                  | 37 (35.92)            | 93 (90.29)             |         |
|      | No                                                                   | 66 (64.08)            | 10 (9.71)              |         |
| 9    | Is there any nearby ADR reporting and monitoring center in your      |                       |                        | <0.0001 |
|      | knowledge?                                                           |                       |                        |         |
|      | Yes                                                                  | 27 (26.21)            | 76 (73.78)             |         |
|      | No                                                                   | 76 (73.78)            | 27 (26.21)             |         |
| 10   | Are you aware of PvPI android application?                           |                       |                        | <0.0001 |
|      | Yes                                                                  | 7 (6.79)              | 82 (80.58)             |         |
|      | No                                                                   | 96 (93.21)            | 20 (19.42)             |         |
| 11   | Are you aware of PvPI toll-free number?                              |                       |                        | <0.0001 |
|      | Yes                                                                  | 9 (8.73)              | 83 (80.58)             |         |
|      | No                                                                   | 94 (91.27)            | 20 (19.42)             |         |
| 12   | Do you think reporting ADR is necessary?                             |                       |                        | <0.0001 |
|      | Yes                                                                  | 79 (76.69)            | 101 (98.10)            |         |
|      | No                                                                   | 24 (23.31)            | 2 (1.90)               |         |
| 13   | Do you think reporting ADR will increase patient safety?             |                       |                        | <0.0001 |
|      | Yes                                                                  | 76 (73.78)            | 99 (96.11)             |         |
|      | No                                                                   | 27 (26.21)            | 4 (3.89)               |         |
| 14   | Do you worry about legal problems while you think of ADR reporting?  |                       |                        | 0.0190  |
|      | Yes                                                                  | 62 (60.19)            | 24 (23.30)             |         |
|      | No                                                                   | 41 (39.81)            | 79 (76.70)             |         |
| 15   | What is your opinion about establishing ADR monitoring center in     |                       |                        | <0.0001 |
|      | every hospital?                                                       |                       |                        |         |
|      | Should be in every hospital                                           | 70 (67.96)            | 98 (95.14)             |         |
|      | Not necessary in every hospital                                       | 6 (5.82)              | 0                      |         |
|      | One in a city is sufficient                                            | 4 (3.88)              | 2 (1.94)               |         |
|      | Depends on number of bed size in the hospitals                        | 23 (22.34)            | 3 (2.92)               |         |
| 16   | Do you think Pharmacovigilance should be taught in detail to        |                       |                        | <0.0001 |
|      | healthcare professionals?                                             |                       |                        |         |
|      | Yes                                                                  | 73 (70.87)            | 98 (95.14)             |         |
|      | No                                                                   | 30 (29.12)            | 5 (4.86)               |         |
| 17   | Have you reported any ADR so far?                                    |                       |                        | <0.0001 |
|      | Yes                                                                  | 21 (20.38)            | 50 (48.54)             |         |
|      | No                                                                   | 82 (79.62)            | 53 (51.46)             |         |
| 18   | Have you ever counseled the patient regarding ADRs?                  |                       |                        | <0.0001 |
|      | Yes                                                                  | 26 (25.24)            | 61 (59.22)             |         |
|      | No                                                                   | 76 (73.76)            | 41 (39.78)             |         |

ADRs: Adverse drug reactions, PvPI: Pharmacovigilance Program of India, KAP: Knowledge, attitude, and perception
intervention. Question 16 shows that 70.87% pre-KAP to 95.14% post-KAP results suggest that all healthcare professionals should be educated in depth about Pharmacovigilance program. From our study, it has been noticed that a maximum number of participants are having a positive attitude toward Pharmacovigilance program which is a welcome sign toward PvPI. The actual reporting was very low, even when ADR reporting was considered to be important by a majority of the respondents. Previous studies also establish that underreporting of ADRs is a worldwide phenomenon [7,11,35,36]. While it is important to note that these studies were carried out among physicians, several other studies involving nurses have indeed confirmed that underreporting of ADRs is common to all healthcare professionals [31,32]. To improve the ADR reporting, there is a direct need of knowing the reasons for underreporting [37].

Fig. 2 shows the reasons for underreporting in our study, which was lack of knowledge, difficulty to pinpoint suspect drugs, and busy schedule. This was supported by the study conducted by Chatterjee et al. [38], which stated that the clinical negligibility of the adverse reaction due to lack of time and little knowledge about the types of reactions to be preferentially reported are the main reason for underreporting of ADRs. Fig. 3 shows the methods preferred for ADR reporting in which the results of pre-KAP show the lack of awareness in the participants about the existence of various reporting tools.

The post-KAP results reflect positive response toward using information technology in ADR reporting. The overall study findings suggest the need for periodic awareness programs for the healthcare professionals regarding the ADR monitoring program in the hospital and the ADR reporting procedure. This might encourage the healthcare professionals to actively participate in the ADR reporting.

CONCLUSION

The influence on ADR reporting strongly lies on the knowledge and attitudes. The lack of knowledge and negative perceptions about Pharmacovigilance and ADR reporting would lead to ADR underreporting. To resolve the deficits in the practice of ADR reporting among nursing staff, it is necessary to create awareness on the importance of reporting, the reporting system, and their obligation to report ADRs. Majority of respondents agreed that reporting of ADR and teaching teaching healthcare professionals in detail about Pharmacovigilance are necessary. Further, our study strongly suggested that healthcare professionals, especially nursing staff, should be trained on ADR reporting since they are in closer association with patients.

LIMITATION

The present study was done only on nursing professionals from two hospitals. There is a scope for the study in larger group of nursing professional.

ACKNOWLEDGMENT

Logistical and technical support given by Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission, Ghaziabad, India.

AUTHORS CONTRIBUTION

Dharini and Nagarjuna reddy collected data and Pramod kumar and Deepalakshmi helped in statistics.

CONFLICTS OF INTEREST

None declared

REFERENCES

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
3. World Health Organization. Requirements for Adverse Reaction Reporting. Geneva, Switzerland: World Health Organization; 1975.
4. Hanafi S, Torkamandi H, Hayatshahi A, Gholami K, Javadi M. Knowledge, attitudes and practice of nurses regarding adverse drug reaction reporting. Iran J Nurs Midwifery Res 2012;17:21-5.
5. Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Intern Med 2003;18:57-60.
6. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the united states, 1969-2002: The importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9.
7. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf 2006;29:385-96.
8. Moride Y, Haramburu F, Roquejo AA, Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997;43:177-81.
9. Holey E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001;358:1872-3.
10. Figueiras A, Tato F, Fontaïnas J, Gestal-Otero JJ. Influence of physicians’ attitudes on reporting adverse drug events: A case-control study. Med Care 1999;37:809-14.
11. Williams D, Feely J. Underreporting of adverse drug reactions: Perceptions of Irish doctors. Ir J Med Sci 1999;168:257-61.
12. Perlk F, Slanar O, Smid M, Petrácek J. Attitude of Czech physicians to adverse drug reaction reporting. Eur J Clin Pharmacol 2002;58:367-9.
13. Bellon KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995;39:223-6.
14. Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians’ knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiology 2002;55:945-50.
15. Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Physicians’ attitudes and adverse drug reaction reporting: A case-control study in Portugal. Drug Saf 2005;28:825-33.
16. Smith CC, Bennett PM, Pearce HM, Harrison PJ, Reynolds DJ, Aronson JK, et al. Adverse drug reactions in a hospital general medical unit meeting notification to the committee on safety of medicines. Br J Clin Pharmacol 1996;42:423-9.
17. Feely J, Moriarty S, O’Connor P. Stimulating reporting of adverse drug reactions by a fee. BMJ 1990;300:22:3.
18. Shaka SS, Bina G, Pandey R, Rao SP, Singh V, Amber V. Importance of pharmacovigilance in Indian pharmaceutical industry. Asian J Res Pharm Sci 2012;2:4-8.
19. Von Lauve NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: A review of literature. Wien Klin Wochenschr 2003;115:407-15.
20. Wu WK, Pantaleo N. Evaluation of outpatient adverse drug reactions leading to hospitalization. Am J Health Syst Pharm 2003;60:253-9.
21. Aziz Z, Siang TC, Baduradin US. Reporting of adverse drug reactions: Predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf 2007;16:223-8.
22. Oisson S. The need for pharmacovigilance. In: Gupta SK, editor. Pharmacology and Therapeutics in the New Millennium. New Delhi: Narosa Publishing House; 2001. p. 502-8.
23. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009;9:14.
24. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol 2001;51:81-6.
25. Subish P, Izham M, Mishra P. Evaluation of the knowledge, attitude and practices on adverse drug reactions and pharmacovigilance among healthcare professionals in a Nepalese hospital: A preliminary study. Int J Pharm 2007;6:1-5.
26. Rajesh R, Vidyasagar S, Nandakumar K. Retracted by plagiarism: A case report. Indian J Med Sci 2006;60:869-71.
27. Ministry of Health and Family Welfare, Government of India. Pharmacovigilance Programme of India 2010. CDSCO, Ministry of Health and Family Welfare, Government of India; 2010.
28. Hajibe G, Mortazavi SA, Salamzadeh J, Zian A. A survey of knowledge, attitude and practice of nurses towards pharmacovigilance in Taleqani hospital. Iran J Pharm Res 2010;9:199-206.
29. Ulfsvarson J, Mejyr S, Bergman U. Nurses are increasingly involved in pharmacovigilance in Sweden. Pharmacoepidemiol Drug Saf 66
2007;16:532-7.
30. Backstrom M, Mjorndal T, Dahlqvist R. Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf 2000;11:647-50.
31. Shalini S, Mohan S. A study on the awareness and attitude towards pharmacovigilance and adverse drug reaction reporting among nursing students in a private university, Malaysia. Int J Curr Pharm Res 2015;7:84-9.
32. Arjun TN, Sudhir H, Gouraha A, Jain S, Chavan K, Dayma A. Assessment of knowledge, attitude and practice related to pharmacovigilance among the healthcare professionals in a teaching hospital in central India: An questionnaire study. World J Pharm Pharm Sci 2015;4;785-99.
33. Patil A, Gurav YA, Thorat MB, Walsangikar SD. Survey of pharmacovigilance awareness among healthcare professionals. Int J Pharm Ther 2014;4:31-4.
34. Kamtane RA, Jayawardhani V. Knowledge, attitude and perception of physicians towards Adverse drug reaction reporting: A Pharmacoepidemiological study. Int J Pharm Pharm Sci 2012;4:698-704.
35. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res 2015;6:45-52.
36. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf 2009;32:19-31.
37. Sindhuja CH, Shafiya begum SK, Suryateja P, Sudha P. Knowledge, attitude and behavior of community pharmacists towards adverse drug reactions. Int J Pharm Pharm Sci 2015;7:258-61.
38. Chatterjee S, Lyle N, Ghosh S. A survey of the knowledge, attitude and practice of adverse drug reaction reporting by clinicians in eastern India. Drug Saf 2006;29:641-2.